Broadly neutralizing antibodies against influenza A viruses, Fully human, CR6261, diridavumab

$1,999.00
In stock
Catalog
A90004
Bulk Inquiry

Broadly neutralizing antibodies against influenza A viruses, Fully human, CR6261, diridavumab

Clone CR6261         Catalog#: A90004

 

Description:  CR6261 (diridavumab) is fully human neutralizing monoclonal antibody against influenza A. CR6261 recognizes a highly conserved helical region in the membrane-proximal stem of HA1 and HA2. The antibody neutralizes the virus by blocking conformational rearrangements associated with membrane fusion. The CR6261 epitope identified here should accelerate the design and implementation of improved vaccines that can elicit CR6261-like antibodies, as well as antibody-based therapies for the treatment of influenza.

 

 

Isotype:

IgG1

Species reactivity:

Human

Production:

Tissue culture

Purification:

Protein A

Applications:

Neutralization assay, In vivo protection etc.

Storage: 

Store at +4°C short term (1-2 weeks). Store at -20°C long term.

Formulation:

PBS, pH 7.4, Filter sterilized. Endotoxin level tests less than 0.06 EU/ug.

Clonality:

Monoclonal

 

Reference:                           

  1. Ekiert DC, et al. (2009). Antibody recognition of a highly conserved influenza virus epitope..Science. 2009 Apr 10;324(5924):246-51.

 

  1. Friesen RH, et al. (2010). New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.PLoS One. 2010 Feb 8;5(2):e9106.
Write Your Own Review
You're reviewing:Broadly neutralizing antibodies against influenza A viruses, Fully human, CR6261, diridavumab
Your Rating